Spruce Biosciences Inc
SPRB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$113.31M
Close$
$62.84
34.8% upside
Current Fair Value
34.8% upsideUndervalued by 34.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $113.31 Million |
|---|---|
| Enterprise Value | $19.76 Million |
| Earnings per Share | $-50.83 |
| Beta | 3.3 |
| Outstanding Shares | 2,431,075 |
Return
| Return on Equity | -61.33% |
|---|---|
| Return on Assets | -49.93% |
| Return on Invested Capital | -51.79% |
Valuation & Multiples
| P/E Ratio | -1.14 |
|---|---|
| PEG | -0.17 |
| Price to Sales | - |
| Price to Book Ratio | 1.37 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.42 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-8.12
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-5.68
Consensus analyst estimateRevenue Estimate
$50.00 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 82.74% |
|---|---|
| Total Invested | $13,750▼ 99.99% |
| Investors Holding | 4▼ 61.00% |
About Spruce Biosciences Inc
17 employees
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product cand...